ArticleACS pharmacology & translational science2025
Alpha-Lipoic Acid Reduces Methemoglobin and Oxidative Imbalance in the Blood and Liver Induced by Dapsone in Mice: Molecular Mechanism of Antioxidant Action.
Article in ACS pharmacology & translational science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Sodium R-lipoate protects against psoriatic skin inflammation via modulating IL-23/IL-17A axis, oxidative stress, and mast cell activation.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dapsone (DDS) is a sulfone clinically used in the treatment of dermatological disorders, such as dermatitis herpetiformis and psoriasis, besides , , and infections. However, the chronic use of DDS can lead to adverse effects involving all organ systems, such as dapsone hypersensitivity syndrome, methemoglobinemia, hemolytic anemia, and liver injury. These effects probably occur due to the presence of its toxic metabolite DDS-NOH, which can generate reactive oxygen species (ROS), and iron overload, causing oxidative stress. In this sense, antioxidant compounds with chelating properties such as Alpha-lipoic acid (ALA) may be an interesting adjuvant therapy strategy in treating or preventing oxidative stress and adverse reactions related to DDS. This study showed that DDS 40 mg/kg increased the methemoglobin and induced oxidative stress in the erythrocytes and liver of mice. However, post-treatment with ALA 12.5 mg/kg was able to restore redox status and hepatic biomarkers in DDS-intoxicated animals. Thus, inhibiting the formation of methemoglobin and lipid peroxidation in the blood, as well as reducing iron accumulation and production of hepatic enzymes stimulated by DDS metabolism. In addition, the molecular docking shows that ALA in its oxidized form can inhibit DDS-NOH. These findings highlight the potential of ALA and its thiol derivatives as antioxidants in counteracting the harmful effects of DDS metabolites. However, further investigations are necessary to understand the therapeutic potential and antioxidant mechanisms of ALA and its derivatives for the development of new strategies to prevent or alleviate oxidative damage associated with DDS treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.